Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Provectus Biopharmaceuticals Inc PVCT

Healthcare
Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing immunotherapy medicines for different diseases that are based on a class of synthetic small-molecule immuno-catalysts called halogenated xanthenes (HXs). The Company’s lead molecule is named rose bengal sodium (RBS). The Company’s small molecule HX medical science platform... see more

Recent & Breaking News (OTCQB:PVCT)

Provectus Announces Name Change to Provectus Biopharmaceuticals, Inc. and Reincorporates in Delaware

Business Wire December 17, 2013

TrendingWallStreet.com Performs Data Research on PVCT, TWTR, INSY, and NNRX

Accesswire December 14, 2013

TrendingWallStreet.com Starts Volume Coverage on HLT, CYTR, MDDD, and PVCT

Accesswire December 13, 2013

TrendingWallStreet.com Announces Trend Coverage on S, PVCT, IMSC, and FTR

Accesswire November 18, 2013

Provectus to Hold Special Meeting of Stockholders December 16, 2013, in Knoxville, Tennessee

Business Wire November 5, 2013

Small Cap Stocks In Focus - SGLB, NAMG and PVCT

Accesswire October 28, 2013

New Small Cap Reports on FLPC, IWSY, GSAT and PVCT

Accesswire October 25, 2013

Provectus Awarded PV-10 Patent by U.S. Patent and Trademark Office

Business Wire October 24, 2013

New Equity Reports on ONCS, PVCT and HEMP

Accesswire October 24, 2013

Exploratory Data Analyses of Intralesional PV-10 Clinical Phase 2 Study Results Presented at ECC 2013 Demonstrate Effective Locoregional Disease Control and Support Systemic Immunologic Activity in Refractory Metastatic Melanoma

Business Wire September 30, 2013

Goldman Sachs Initiates Sell on IAMGOLD with a $3 Target

Accesswire September 23, 2013

BUYINS.NET Updates Provectus Pharmaceuticals SqueezeTrigger Report

Business Wire September 20, 2013

Provectus Pharmaceuticals CFO Peter Culpepper Interviewed by The Life Sciences Report

Marketwired September 19, 2013

OtcbbJournal.com, Delivers the Most Sought After Micro-Cap Stock Research

Marketwired September 16, 2013

Provectus to Present Additional Results in 80 Patient International Multicenter Phase 2 Clinical Trial in Metastatic Melanoma at European Cancer Congress 2013

Business Wire September 12, 2013

OtcbbJournal.com Delivers the Most Sought After Micro-Cap Stock Research in the Business

Marketwired September 4, 2013

Research on Mechanism of Action of Rose Bengal Presented at 8th World Congress of Melanoma

Business Wire August 6, 2013

PV-10 Data on Locoregional Disease Control in Metastatic Melanoma to Be Presented at European Cancer Congress 2013

Business Wire June 24, 2013

Provectus Receives Patent Allowance from U.S. Patent and Trademark Office

Business Wire June 5, 2013

Provectus Updates Shareholders in Its Annual CEO Letter

Business Wire May 13, 2013